These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24455986)

  • 1. Harvard Catalyst | The Clinical Translational Science Center IND/IDE Consult Service: providing an IND/IDE consult service in a decentralized network of academic healthcare centers.
    Kim MJ; Winkler SJ; Bierer BE; Wolf D
    Clin Transl Sci; 2014 Apr; 7(2):150-5. PubMed ID: 24455986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Support for investigator-initiated clinical research involving investigational drugs or devices: the Clinical and Translational Science Award experience.
    Berro M; Burnett BK; Fromell GJ; Hartman KA; Rubinstein EP; Schuff KG; Speicher LA;
    Acad Med; 2011 Feb; 86(2):217-23. PubMed ID: 21169787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations from the Investigational New Drug/Investigational Device Exemption Task Force of the clInical and Translational Science Award Consortium: developing and implementing a sponsor-investigators training program.
    Holbein ME; Berglund JP; O'Reilly EK; Hartman K; Speicher LA; Adamo JE; O'Riordan G; Brown JS; Schuff KG;
    J Investig Med; 2014 Jun; 62(5):797-803. PubMed ID: 24831858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A program to provide regulatory support for investigator-initiated clinical research.
    Arbit HM; Paller MS
    Acad Med; 2006 Feb; 81(2):146-53. PubMed ID: 16436575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding Food and Drug Administration regulatory requirements for an investigational device exemption for sponsor-investigators.
    Holbein ME; Berglund JP
    J Investig Med; 2012 Oct; 60(7):987-94. PubMed ID: 22847340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators.
    Holbein ME
    J Investig Med; 2009 Aug; 57(6):688-94. PubMed ID: 19602987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs.
    Hata T; Nakamura K; Yonemori K; Noguchi E; Watanabe M; Sohn J; Lu YS; Yap YS; Tamura K; Fujiwara Y
    Clin Transl Sci; 2021 May; 14(3):1015-1025. PubMed ID: 33382914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The investigator-sponsored IND in clinical trials.
    Haakenson C; Fye CL; Sather MR; Toussaint DJ
    Control Clin Trials; 1987 Jun; 8(2):101-9. PubMed ID: 3608504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CTSA institutes and academic medical centers in facilitating preapproval access to investigational agents and devices during the COVID-19 pandemic.
    Gravelin M; Wright J; Holbein MEB; Berro M; Brown JS; Mashour GA; Weatherwax KJ
    J Clin Transl Sci; 2021 Feb; 5(1):e94. PubMed ID: 34192051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical delivery of cultured stem cells to human non-healing wounds: GMP facility development in an academic setting and FDA requirements for an IND and human testing.
    Yufit T; Carson P; Falanga V
    Curr Drug Deliv; 2014; 11(5):572-81. PubMed ID: 23517627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials.
    Perez R; Archdeacon P; Roach N; Goodwin R; Jarow J; Stuccio N; Forrest A
    Clin Trials; 2017 Jun; 14(3):225-233. PubMed ID: 28345368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The US Food and Drug Administration investigational device exemptions (IDE) and clinical investigation of cardiovascular devices: information for the investigator.
    Pritchard WF; Abel DB; Karanian JW
    J Vasc Surg; 1999 Mar; 29(3):566-74. PubMed ID: 10069924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The US Food and Drug Administration investigational device exemptions and clinical investigation of cardiovascular devices: information for the investigator.
    Pritchard WF; Abel DB; Karanian JW
    J Vasc Interv Radiol; 1999 Feb; 10(2 Pt 1):115-22. PubMed ID: 10082096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials integrity: a CRO perspective.
    Beach JE
    Account Res; 2001; 8(3):245-60. PubMed ID: 12481762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products.
    Manning ML; Thompson MD; Saber H; Maher VE; Crich JZ; Leighton JK
    Regul Toxicol Pharmacol; 2020 Feb; 110():104511. PubMed ID: 31678263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?
    Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE
    Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical devices; procedures for investigational device exemptions--Food and Drug Administration. Final rule.
    Fed Regist; 1980 Jan; 45(13):3732-59. PubMed ID: 10248822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA oversight of NSIGHT genomic research: the need for an integrated systems approach to regulation.
    Milko LV; Chen F; Chan K; Brower AM; Agrawal PB; Beggs AH; Berg JS; Brenner SE; Holm IA; Koenig BA; Parad RB; Powell CM; Kingsmore SF
    NPJ Genom Med; 2019; 4():32. PubMed ID: 31839987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Limits of FDA's Authority to Regulate Clinical Research Involving High-Throughput DNA Sequencing.
    Evans BJ
    Food Drug Law J; 2015; 70(2):259-87, ii. PubMed ID: 26302600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.